Bijoy Menon

Dr. Bijoy Menon

MBBS, MD, DM, MSc, FRCPC

Positions

Professor

Cumming School of Medicine, Department of Clinical Neurosciences

Professor

Cumming School of Medicine, Department of Community Health Sciences

Professor

Cumming School of Medicine, Department of Radiology

Full Member

Hotchkiss Brain Institute

Contact information

Web presence

For media enquiries, contact

Kelly Johnston
Senior Communications Specialist

Please submit your media request here

 

Background

Biography

Bijoy Menon is a Neurologist and a Professor in the Departments of Neurosciences, Radiology and Community Health Sciences at the University of Calgary. He leads an internationally recognized research program that is pushing the boundaries of modern stroke care by using advanced image processing techniques, statistical and clinical trial methodologies and Artificial Intelligence based algorithms to develop cutting edge imaging tools and better treatment for people suffering from acute stroke. He is a member of the Royal Society of Canada's College of New Scholars, Artists and Scientists and recipient of the Michael S. Pessin Stroke Leadership award from the American Academy of Neurology, the Avenue Magazine Top 40 under 40 award (2014), a CIHR New Investigator Award (2015-2020), a University of Calgary/Heart and Stroke Professorship in Stroke Imaging (2014-2020) and the 2015 University of Calgary PEAK Scholarship in Entrepreneurship Innovation & Knowledge Translation. He is founder and Chief Medical Officer for Circle NVI Inc, a University of Calgary spin-off company that is developing cutting edge imaging and communication solutions for use in acute stroke.

 

Research

Participation in university strategic initiatives

Projects

AcT RRCT

AcT  is a Pragmatic Phase III randomized open-label registry-based trial with blinded end-point assessment. Enrolled acute ischemic stroke patients will be eligible to receive intravenous thrombolysis (Alteplase or Tenecteplase) as per current guidelines.

Over the three year study period, 1,600 patients will be treated with tPA or TNK, with followup at 90 days. The primary outcome measure will be a modified Rankin Scale (mRS) 0 or 1 at 90-120 days.

A description of this clinical trial is available on http://www.ClinicalTrials.gov  ClinicalTrials.gov Identifier: NCT03889249

 

Publications